GLOBAL PLASMA PROTEIN THERAPEUTIC MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

The Global Plasma Protein Therapeutic Market size is expected to reach US$ 46.49 Bn by 2030, from US$ 29.97 Bn in 2023, exhibiting a CAGR of 6.5% during the forecast period.

Plasma protein therapeutics are derived from human blood plasma and are used for treating several chronic and serious diseases. There are mainly four types of plasma protein products available commercially. The first is immunoglobulins, which are antibodies that help fight infections and diseases. They are used to treat primary immunodeficiencies and neurological disorders. The second is clotting factors which are used for treating hemophilia. Clotting factor concentrates help replace clotting factors that are missing or low in hemophiliacs. The third type is albumins which maintain proper fluid balance in the body and are used in emergency situations to replace lost fluid. The final category is protease inhibitors which regulate processes in the body and are used for treating hepatitis C.

Global Plasma Protein Therapeutic Market - Regional Insights

• North America is expected to be the largest market for plasma protein therapeutic during the forecast period, accounting for over 35.7% of the market share in 2023. North America has emerged as the dominant region in the global plasma protein therapeutic market over the past decade. The U.S. accounts for the largest share due to the strong presence of leading plasma fractionation companies and established plasma collection centers network across the country. Growing demand for immunoglobulin’s and albumin to treat various bleeding and immunodeficiency disorders has kept North America at the top. Favorable regulatory environment and comprehensive healthcare insurance coverage have further strengthened the market position.
• Asia Pacific is expected to be the second-largest market for the plasma protein therapeutic, accounting for over 25.2% of the market share in 2023. Asia Pacific, on the other hand, has witnessed the fastest growth and is expected to become the new attractive destination for plasma protein therapeutic companies. China represents a major opportunity due to rising healthcare investments, growing middle-class population, and increasing access to modern medical treatments. In addition, the cost of production and operations is relatively lower in China attracting several Western companies to establish local production sites through joint ventures. This has played an important role in meeting the huge domestic demand and reducing dependency on imports. India is another emerging market with strong future potential. Initiatives by the government towards plasma collection infrastructure and promotion of plasma fractionation projects are positively impacting the industry.
• Europe is expected to be the fastest-growing market for plasma protein therapeutic, growing at a share of 19% during the forecast period. The growth of the market in Europe is attributed to the increasing prevalence of complement deficiency diseases in the region.

Figure 1. Global Plasma Protein Therapeutic Market Share (%), By Region, 2023

To learn more about this report, request a free sample copy

Analyst’s Views: The global plasma protein therapeutic market has significant growth potential over the forecast period. The increasing prevalence of immunodeficiency diseases and growing aging population who are more prone to chronic diseases will drive the demand for plasma protein therapeutics. North America currently dominates the market owing to a developed healthcare infrastructure and rising expenditure on healthcare. However, Asia Pacific is expected to be the fastest growing region due to rising healthcare standards, large patient pool, and growing medical tourism.          

Global Plasma Protein Therapeutic Market- Drivers

• Increasing prevalence of complement deficiency diseases: There is a steady rise in the number of people suffering from complement deficiency diseases across the world. Complement deficiency diseases are a group of disorders caused by defects in the complement system which is an important part of the immune system. Complement proteins play a crucial role in fighting infections and clearing immune complexes and dead cells. When any component of the complement system is lacking or not functioning properly, it leaves the individual vulnerable to recurrent and severe infections. According to recent studies and statistics published by leading healthcare agencies, the incidence and prevalence of complement deficiency diseases like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), myasthenia gravis and Guillain-Barré syndrome are increasing globally. This is mainly attributed to improved diagnostic methods that aid early detection of these previously under-diagnosed disorders as well as aging population prone to acquire such conditions. The rising patient pool suffering from complement deficiency disorders is driving significant the demand for plasma protein therapeutics that help replace or supplement the deficient complement protein in the body and prevent complications.
• Greater clinical efficacy of plasma protein therapeutics: Another key factor supporting the growth of the plasma protein therapeutic market is their proven clinical effectiveness compared to conventional drug therapies for certain chronic and rare diseases. Plasma derived therapies represent an important treatment option for many orphan and genetic conditions due to their high specificity and ability to closely substitute the naturally occurring human protein. For instance, plasma protein therapies have shown encouraging results in managing hemophilia which requires life-long prophylactic administration. They have considerably reduced bleeding episodes and improved quality of life for thousands of hemophilia patients worldwide. Similarly, immune globulin therapies are highly effective against several autoimmune disorders like immune thrombocytopenia by dampening overactive immune response. As more clinical evidence emerges to demonstrate the clear benefits of plasma protein therapeutics like lower mortality and morbidity over synthetic drugs in treating rare bleeding, neurological and respiratory diseases, their demand from healthcare community and patients is accelerating significantly.
• Increasing plasma collection: Increasing plasma collection significantly propels the growth of the global plasma protein therapeutic market through various mechanisms:
• • Enhanced Product Availability: An increase in plasma collection leads to a higher availability of essential plasma-derived proteins, ensuring steady supply chains for plasma protein therapeutics
  • Diverse Treatment Options: More plasma collection facilitates the production of a broader range of plasma protein products from immunoglobulins to clotting factors, satisfying various therapeutic needs
  • Meeting Patient Demands: The growth in patient populations requiring plasma protein treatments for conditions like immune deficiencies, hemophilia, and other rare diseases necessitates increased plasma collection to meet these demands.
  • Global Health Initiatives: Heightened efforts to collect plasma can be driven by global health initiatives aiming to improve access to life-saving plasma protein therapies in both developed and developing countries.

Global Plasma Protein Therapeutic Market- Opportunities

• Immune globulin for various disease treatment: The use of immune globulin in the treatment of various diseases significantly propels the growth of the global plasma protein therapeutic market through the following factors:
  • Broad Therapeutic Application: Immune globulin is used in the treatment of a wide range of conditions including primary immunodeficiencies, autoimmune diseases, and infectious diseases, which creates extensive demand for these therapies
  • Increased Prevalence of Diseases: The rising prevalence of diseases that require immune globulin therapy directly contributes to an increase in consequently drives market growth
  • Advancements in Treatments: Continued research and development have led to more precise and targeted applications of immune globulin, expanding its usage in new therapeutic areas
  • Improved Diagnosis: Better diagnostic techniques are leading to earlier and more accurate identification of diseases that can be treated with immune globulin, thereby increasing the patient pool
• Growing healthcare expenditure: One of the significant factors influencing the growth rate of the global plasma protein therapeutic market is the growing healthcare expenditure, which helps in improving its infrastructure. For instance, according to the International Health Care System of the U.S., in June 2020, U.S. government organizations aim to improve the healthcare infrastructure by increasing funding, setting legislation and national strategies, and cofounding and setting basic requirements and regulations for the Medicaid program. Similarly, in November 2022, the Canadian Institute for Health Information reported that the total health spending in Canada was US$ 331 billion in 2022, or US$ 8,563 per Canadian, while health expenditure represented 12.2% of Canada's gross domestic product (GDP) in 2022, following a high of 13.8% in 2020.
• New plasma protein indications: The discovery of new plasma protein indications is a strong growth catalyst for the global plasma protein therapeutic market due to the following reasons:
  • Expanding Treatment Horizons: Identifying new therapeutic uses for plasma proteins can significantly broaden the range of treatable conditions, creating additional demand for plasma protein therapies
  • Driving Research and Development: The potential for new indications stimulates investment and innovation in research, advancing the development of novel plasma protein products
  • Enhancing Market Potential: With each new indication, the market potential for plasma protein therapeutics increases, inviting both established and new players to invest and compete in the market
  • Improving Patient Care: The development of treatments for previously unaddressed medical needs enhances patient care and can improve quality of life for individuals with rare and chronic diseases.
  • Attracting Funding: New indications attract funding for clinical trials and research, further propelling the growth of plasma protein therapeutics.

Global Plasma Protein Therapeutic Market- Trends

• Alternate fractionation process: The deployment of alternative fractionation processes can propel the growth of the global plasma protein therapeutic market in several key ways:
  • Enhanced Efficiency: Alternate fractionation techniques may offer improved efficiency over traditional methods, reducing production time and costs while increasing yield
  • Innovation in Production: These new processes can stimulate innovation in the field, leading to the development of more effective and safer plasma protein products
  • Increased Capacity: Alternative processes allow for increased production capacity to meet the growing global demand for plasma protein therapeutics
  • Product Purity and Safety: New fractionation methods can result in higher purity and safety profiles for plasma protein products, which is critical for patient care and regulatory compliance
• Increasing albumin demand: The increasing demand for albumin drives the growth of the global plasma protein therapeutic market in several significant ways:
  • Expanding Clinical Applications: As albumin is recognized for its role in several clinical applications, including volume replacement and shock, liver disease treatment, and as a carrier for other therapeutics, the range of its use widens, fueling the market growth
  • Aging Population: The growing geriatric population, with its associated susceptibility to diseases that require albumin, such as liver conditions and kidney diseases, increases the demand for albumin-based treatments
  • Rising Prevalence of Diseases: The higher prevalence of disease states that necessitate albumin therapies, such as trauma, burns, and sepsis, directly contributes to the heightened requirement for albumin
  • Research and Development: Ongoing research that uncovers new therapeutic uses for albumin can extend its market presence and applications, adding to the market dynamism

Global Plasma Protein Therapeutic Market - Restraints

• High cost of plasma protein therapeutic: The high cost of plasma protein therapeutics can hinder the growth of the global plasma protein therapeutic market through several mechanisms:
  • Financial Barriers: High prices may make it difficult for patients, especially those in low- and middle-income countries, to afford these treatments, reducing overall market access and penetration
  • Budget Constraints for Healthcare Systems: Healthcare providers may face budget constraints that limit the purchase and use of expensive therapeutics, impacting the volume of sales and market expansion
  • Insurance Coverage Limitations: Insurance coverage may be restrictive or inadequate for high-cost plasma protein therapies, leading to underutilization due to out-of-pocket expense concerns
• Supply and Demand mismatch: A mismatch between supply and demand can hinder the growth of the global plasma protein therapeutic market in several significant ways:
• • Treatment Delays: A deficit in supply relative to demand can lead to delays in the treatment of patients who rely on plasma protein therapies for managing their conditions
  • Price Volatility: Imbalances in supply and demand can cause price fluctuations, which may make budgeting and financial planning challenging for healthcare providers and patients
  • Accessibility Issues: When supply cannot meet demand, certain regions or patient groups may experience reduced accessibility to plasma protein therapeutics, leading to disparities in care
  • Strain on Production: Adequate plasma protein supply is dependent on a robust and efficient production chain; mismatches can strain existing production capabilities and logistics, adversely affecting the global plasma protein therapeutic market

Figure 2. Global Plasma Protein Therapeutic Market Share (%), By Product Type, 2023

To learn more about this report, request a free sample copy

Global Plasma Protein Therapeutic Market- Recent Developments

Product Approval and Launch

• In October 2022, Grifols, a global leader in plasma medicines, announced that its drug TAVLESSE (fostamatinib), used to treat chronic immune thrombocytopenia (ITP) in adult patients refractory to other treatments, is now recommended by the National Institute for Health and Care Excellence (NICE)
• In March 2022, Terumo Blood and Cell Technologies, a company specializing in medical devices, received approval from the U.S. Food and Drug Administration (FDA) for its innovative plasma collection system known as the Rika Plasma Donation System (Rika). This state-of-the-art automated system is designed to enhance the experience for both donors and plasma center staff, signaling a new era in plasma donation technology.

Business Development Activities by Market Players

• In October 2022, Grifols, a biopharmaceutical company, announced the official opening of its advanced production facility located in Ireland. This strategic expansion aims to address the increasing international demand for plasma-derived medicines. With this move, the production capacity of Grifols' ALBUTEIN FlexBag—a novel and adaptable packaging solution for albumin, the most common protein found in plasma—has experienced a threefold surge, ensuring a steady supply of this crucial plasma product.
• In August 2022, Terumo Blood and Cell Technologies, a medical technology company, announced that its new Rika Plasma Donation System successfully completed the first plasma donation in a plasma collection center, operated by CSL Plasma, a global leader in plasma collection.
• In September 2021, Grifols announced that TAVLESSE (fostamatinib), used to treat chronic immune thrombocytopenia (ITP) in adult patients refractory to other treatments, is available in France, Italy, and Spain and reimbursable from their respective health systems

Top Companies in the Global Plasma Protein Therapeutic Market

• Octapharma USA Inc.
• Biotest AG
• Kedrion S.p.A
• CSL Limited
• Grifols, S.A
• Takeda Pharmaceutical Company Limited.
• Octapharma AG
• Bio Products Laboratory (BPL)
• Shire Plc
• Albumedix Ltd.

Definition: Plasma protein therapeutics are medications that are derived from human blood plasma and are used for treating several medical conditions. There are several types of plasma protein therapeutic products available in the market. The main types include immunoglobulins, coagulation factors, albumin, and other specialty proteins.